{
    "clinical_study": {
        "@rank": "77199", 
        "arm_group": [
            {
                "arm_group_label": "OnabotulinumtoxinA Dose A", 
                "arm_group_type": "Experimental", 
                "description": "OnabotulinumtoxinA Dose A injected into the detrusor wall on Day 1."
            }, 
            {
                "arm_group_label": "OnabotulinumtoxinA Dose B", 
                "arm_group_type": "Experimental", 
                "description": "OnabotulinumtoxinA Dose B injected into the detrusor wall on Day 1."
            }, 
            {
                "arm_group_label": "OnabotulinumtoxinA Dose C", 
                "arm_group_type": "Experimental", 
                "description": "OnabotulinumtoxinA Dose C injected into the detrusor wall on Day 1."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of onabotulinumtoxinA for the treatment of\n      urinary incontinence due to neurogenic detrusor overactivity in pediatric patients between\n      the ages of 8 to 17 years."
        }, 
        "brief_title": "Study of OnabotulinumtoxinA for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Urinary Incontinence", 
        "condition_browse": {
            "mesh_term": "Urinary Incontinence"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Urinary incontinence due to neurogenic detrusor overactivity\n\n          -  Regularly using clean intermittent catheterization to empty the bladder\n\n        Exclusion Criteria:\n\n          -  Surgery of the spinal cord within 6 months\n\n          -  Diagnosis of cerebral palsy\n\n          -  Current or planned use of a baclofen pump\n\n          -  Current or planned use of an electrostimulation/neuromodulation device for urinary\n             incontinence\n\n          -  Use of an indwelling catheter for urinary incontinence instead of using clean\n             intermittent catheterization to empty the bladder\n\n          -  Previous or current use of botulinum toxin therapy of any serotype for any urological\n             condition, or treatment with botulinum toxin of any serotype within 3 months for any\n             other condition or use\n\n          -  Myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "8 Years"
        }, 
        "enrollment": {
            "#text": "132", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01852045", 
            "org_study_id": "191622-120", 
            "secondary_id": "2012-004877-26"
        }, 
        "intervention": {
            "arm_group_label": [
                "OnabotulinumtoxinA Dose A", 
                "OnabotulinumtoxinA Dose B", 
                "OnabotulinumtoxinA Dose C"
            ], 
            "description": "OnabotulinumtoxinA injected into the detrusor wall on Day 1.", 
            "intervention_name": "OnabotulinumtoxinA", 
            "intervention_type": "Biological", 
            "other_name": [
                "BOTOX\u00ae", 
                "botulinum toxin Type A"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 9, 2014", 
        "link": {
            "description": "More information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Innsbruck", 
                        "country": "Austria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Antwerpen", 
                        "country": "Belgium"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hradec Kr\u00e1lov\u00e9", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Naples", 
                        "country": "Italy"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Austria", 
                "Belgium", 
                "Canada", 
                "Czech Republic", 
                "Italy"
            ]
        }, 
        "number_of_arms": "3", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Daily Average Frequency of Daytime Urinary Incontinence Episodes", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 6 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01852045"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Maximum Cystometric Capacity (MCC)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 6"
            }, 
            {
                "measure": "Percentage of Patients With Involuntary Detrusor Contractions (IDC)", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "Change from Baseline in Maximum Detrusor Pressure During the First IDC", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 6"
            }, 
            {
                "measure": "Change from Baseline in Detrusor Leak Point Pressure (DLPP)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 6"
            }, 
            {
                "measure": "Change from Baseline in Average Urine Volume at First Morning Catheterization", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 6 Weeks"
            }, 
            {
                "measure": "Percentage of Patients With Night Time Urinary Incontinence", 
                "safety_issue": "No", 
                "time_frame": "6 Weeks"
            }, 
            {
                "measure": "Change from Baseline in Maximum Detrusor Pressure", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 6"
            }, 
            {
                "measure": "Time to Patient Request for Retreatment", 
                "safety_issue": "No", 
                "time_frame": "48 Weeks"
            }, 
            {
                "measure": "Time to Patient Qualification for Retreatment", 
                "safety_issue": "No", 
                "time_frame": "48 Weeks"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}